Drugmakers in China Explore AI Marketing Amid Anti-Graft Scrutiny

Reuters reported on November 11, 2026 that pharmaceutical companies in China are exploring marketing through medical AI assistants and customized disease-specific academic platforms as stricter anti-corruption enforcement complicates traditional visits to doctors and hospitals. The opportunities fall into two distinct categories. Null Hypothesis CEO Gu Fei said major Chinese and foreign drugmakers have licensed its KnowS product to build physician-facing academic platforms focused on particular...